Precigen (NASDAQ:PGEN – Get Free Report) is expected to release its earnings data before the market opens on Wednesday, March 19th. Analysts expect Precigen to post earnings of ($0.06) per share and revenue of $1.30 million for the quarter.
Precigen Price Performance
Shares of PGEN opened at $1.80 on Monday. The firm has a market capitalization of $527.16 million, a PE ratio of -3.27 and a beta of 1.57. The company’s 50-day moving average is $1.55 and its 200-day moving average is $1.13. Precigen has a fifty-two week low of $0.65 and a fifty-two week high of $2.17.
Analyst Ratings Changes
A number of research firms have recently weighed in on PGEN. HC Wainwright restated a “buy” rating and issued a $6.00 price target (up from $4.00) on shares of Precigen in a research note on Thursday, January 23rd. JMP Securities restated a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $7.00.
About Precigen
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Featured Articles
- Five stocks we like better than Precigen
- Basic Materials Stocks Investing
- How to Build the Ultimate Everything ETF Portfolio
- How to trade penny stocks: A step-by-step guide
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is Forex and How Does it Work?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.